These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 19014836

  • 1. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
    Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J.
    Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
    [Abstract] [Full Text] [Related]

  • 2. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S, Clowse M, Pardo P, Bhattacharya I, Menon S, Gourley I, Diehl A.
    Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
    [Abstract] [Full Text] [Related]

  • 3. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug M, Kneer J, van der Auwera P, Stevens RM, Rheumatology Group 791.
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [Abstract] [Full Text] [Related]

  • 7. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE.
    J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
    [Abstract] [Full Text] [Related]

  • 8. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
    Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W, ACTION Study Group.
    Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2739-46. PubMed ID: 19351771
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP.
    Arthritis Rheum; 2006 Aug 15; 54(8):2377-86. PubMed ID: 16869000
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.